{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-080930","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2026-07-07T11:02:35+00:00","discovered_at":"2026-07-07T11:05:00.258451+00:00","generated_at":"2026-07-07T11:05:05.346642+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tvardi Therapeutics' TTI-109 Phase 1 study confirms prodrug design, improved tolerability, and STAT3 target engagement","bullets":["TTI-109 rapidly converted to TTI-101 within 2 hours, achieving equivalent plasma exposure at molar-equivalent doses.","Diarrhea duration with TTI-109 was 0.46 days vs 3.35 days for TTI-101; similar to placebo.","Pharmacodynamic data showed up to 60% reductions in STAT3-driven immune cell populations (Th17, Tfh, B cells).","Company plans to advance TTI-109 into STAT3-driven dermatologic and GI diseases, subject to additional funding.","No serious adverse events; one discontinuation due to transaminitis deemed unlikely related."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-080930","json":"https://secwatch.observer/filing/0001104659-26-080930.json","markdown":"https://secwatch.observer/filing/0001104659-26-080930.md","text":"https://secwatch.observer/filing/0001104659-26-080930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/0001104659-26-080930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/tm2619879d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T11:05:05.346642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}